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Objective
The objective of this study is to test the efficacy of 
KDM1A inhibition on chemotherapy sensitization 
of glioblastoma cells.
KDM1A inhibition enhances chemotherapy response in glioblastoma 
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Results
Western blot analysis confirmed the knockout and knockdown of 
KDM1A in GBM cells. Cell viability assays showed that KDM1A 
knockout or knockdown potentiated the cytotoxic effect of TMZ in TMZ 
sensitive and TMZ resistant GBM cells. Further, clonogenic survival 
assays demonstrated that KDM1A knockout or knockdown enhanced 
the TMZ efficacy in reducing the cell survival of GBM cells. 
Importantly, qRT-PCR assays showed that KDM1A knock out reduced 
the expression of DNA repair genes and induced the apoptotic gene p21.
Glioblastomas (GBM) have dismal survival rates 
of 1 year – 34.6% and 5 years – 4.75% which 
affects 13,000 patients yearly. As of now, standard 
of care treatment consists of surgical resection, 
external beam radiation therapy, adjuvant 
chemotherapy with temozolomide (TMZ), and 
tumor treating fields. Regardless of the extensive 
therapy, patients will eventually fall victim to this 
deadliest disease. Deregulated oncogenic and 
epigenetic signaling mechanisms contribute to 
chemo and radiation therapy resistance. The 
lysine-specific demethylase-1 (KDM1A/LSD1) 
demethylates both mono- and dimethylated lysine 
residue-4 and -9 specifically on histone H3. 
KDM1A regulates gene expression programs by 
changing the epigenetic histone marks at the gene 
prompters. Emerging studies have shown that 
KDM1A is overexpressed in glioblastoma and 
other cancers. However, the role of KDM1A in 
therapy resistance of GBM remains unknown. In 
this study, we tested the hypothesis that KDM1A 
inhibition sensitizes GBM to TMZ therapy. 
Introduction
Methods
To study the role of KDM1A in GBM cells, we 
have generated KDM1A knockout (KDM1A- 
KO) cells and KDM1A-shRNA transfected 
GBM cells (KDM1A-KD). Confirmation of 
these knockdowns and knockouts was done 
using western blotting. The effect of 
KDM1A-KO and –KD on cell viability and 
survival of U251 and T98G cells was studied 
using MTT cell viability assays and clonogenic 
cell survival assays respectively. A mechanistic 
study was conducted using RT-qPCR which 
examined the expression of DNA repair genes in 
U251 and U251 KDM1A-KO GBM cells.
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Fig. 1. Confirmation of KDM1A-KO and KD in GBM cells
Fig 1 A, Knockdown of KDM1A in T98G was tested using western blotting. 
B, Knockout of KDM1A in U251 was tested using western blotting. 
Fig. 2. KDM1A-KO and –KD sensitize TMZ-sensitive and 
TMZ-resistant GBM cells to TMZ treatment
Fig. 2 A, U251 control and KDM1A-KO cells were treated with various amounts 
of TMZ for 7 days, and the cell viability was determined using MTT assays. B, 
T98G cells expressing control shRNA or KDM1A-shRNA were treated with 
varying amounts of TMZ for 7 days and the cell viability was determined using 
MTT assays. 
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Fig. 3. KDM1A-KO and –KD enhanced the TMZ efficacy in reducing the 
cell survival
A
B
Fig. 3 A, U251 or KDM1A-KO cells were treated with TMZ for 5 days and cell survival was 
determined after 14 days using colony formation assays. B, T98G control shRNA or 
KDM1A-shRNA cells were treated with TMZ for 5 days and cell survival was determined after 
14 days using colony formation assays. 
Fig. 4. Knockout of KDM1A reduced the 
expression of DNA repair genes in GBM cells 
Fig. 4 A, Expression of  DNA repair and apoptosis genes in 
U251 or KDM1A KO was analyzed using RT-qPCR
A
Conclusion
Our results provided the evidence that knockout or knockdown of 
KDM1A sensitizes GBM cells to chemotherapy and may lead to the 
development of KDM1A inhibitor therapy in conjunction with TMZ.
Moraima Rodriguez 
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This research was conducted at The University of Texas Health Science Center in San Antonio, 
TX over the course of 9 months under the supervision of Dr. Gangadhara Sareddy. This study is 
based on the hypothesis that the protein KDM1A could increase chemotherapy response in 
glioblastoma (brain cancer) when inhibited. When conducting this research, we had the previous 
knowledge that a protein known as KDM1A was related to chemotherapy response in 
glioblastoma due to previous research done by Dr. Sareddy in 2017 which indicated that 
KDM1A inhibition induced cell death in glioblastoma stem cells via unfolded protein response 
pathway (as seen in article 4 in the bibliography). This along with other studies that connected 
the inhibition of KDM1A and cell death in glioblastoma cells, allowed us to develop the 
hypothesis that when exposed to different levels of chemotherapy and KDM1A inhibition, there 
would be an increase in the response level of the glioblastoma cells, meaning more cell death 
would be seen. The way we went about testing this was first identifying certain glioblastoma cell 
lines we wanted to work with, which ended up being U251 and T96G. U251 is considered a very 
weak cell line and easy to kill while T98G is a rather difficult cell line to kill. We wanted to see 
two different ends of the spectrum and decided that these two commercial cell lines would be 
appropriate. Once we identified the cell lines we wanted to work with, we inhibited KDM1A 
using a virus and then tested the cell lines using western blot in order to ensure that the protein 
was inhibited. As seen in figure 1 both cell lines had the KDM1A “knockout” or “knockdown” 
which is just another way of saying the protein is no longer active. Western blot confirmed this 
by showing a lack of bands present in the KDM1A knockdown/knockout cell lines. After 
confirming this knockdown/knockout we began by exposing the cell lines to different levels of a 
chemotherapy called temozolomide (TMZ) and comparing those results to the regular cell lines. 
As seen in figure 2, there was a decrease in the amount of cell viability in the knocked out/down 
cell lines. This was done by conducting a MTT assay which is way to expose a cell line to 
multiple levels of something in one trial. After repeating the experiment multiple times, we 
determined that the next step in our journey was to have a visible representation of cell survival 
rates. So in order to do that we conducted colony formations, which showed us how many cell 
colonies formed over a week when exposed to TMZ. We did this with both the regular cell lines 
and the knockdown/out cell lines. As seen in figure 3, there was a significant decrease in the 
amount of cell colonies formed when compared to the vehicle plates. With all this evidence after 
multiple trials we could then say that there was a definite increase in response to chemotherapy 
when KDM1A was inhibited. Even then we wanted to test the function of the cell when KDM1A 
was inhibited, so we used a test called RT-qPCR in order to determine how well DNA repair 
genes and cell death genes were being used in the cell lines. As seen in figure 4, there was a 
significant decrease in the function of both RAD51 and MRE11A which are both DNA repair 
genes. As well as a significant increase in the P21 genes which is a cell death gene, which means 
that more cells were dying and less were being repaired by the genes. With all of this evidence, 
we were able to conclude that knockout or knockdowns of KDM1A sensitized glioblastoma cells 
to chemotherapy and may lead to the development of KDM1A inhibitor therapy in conjunction 
with chemotherapy.  
